| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Shuko Takeda, Susanne Wegmann, Hansang Cho, Sarah L DeVos, Caitlin Commins, Allyson D Roe, Samantha B Nicholls, George A Carlson, Rose Pitstick, Chloe K Nobuhara, Isabel Costantino, Matthew P Frosch, Daniel J Müller, Daniel Irimia, Bradley T Hyma. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain. Nature communications. vol 6. 2016-05-20. PMID:26458742. |
tau pathology is known to spread in a hierarchical pattern in alzheimer's disease (ad) brain during disease progression, likely by trans-synaptic tau transfer between neurons. |
2016-05-20 |
2023-08-13 |
mouse |
| Michiyo Iba, Jennifer D McBride, Jing L Guo, Bin Zhang, John Q Trojanowski, Virginia M-Y Le. Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC's afferent and efferent connections. Acta neuropathologica. vol 130. issue 3. 2016-05-17. PMID:26150341. |
filamentous tau inclusions are hallmarks of alzheimer's disease (ad) and other neurodegenerative tauopathies. |
2016-05-17 |
2023-08-13 |
mouse |
| Yoshiyuki Soeda, Misato Yoshikawa, Osborne F X Almeida, Akio Sumioka, Sumihiro Maeda, Hiroyuki Osada, Yasumitsu Kondoh, Akiko Saito, Tomohiro Miyasaka, Tetsuya Kimura, Masaaki Suzuki, Hiroko Koyama, Yuji Yoshiike, Hachiro Sugimoto, Yasuo Ihara, Akihiko Takashim. Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups. Nature communications. vol 6. 2016-05-17. PMID:26671725. |
neurofibrillary tangles, composed of hyperphosphorylated tau fibrils, are a pathological hallmark of alzheimer's disease; the neurofibrillary tangle load correlates strongly with clinical progression of the disease. |
2016-05-17 |
2023-08-13 |
Not clear |
| Yoshiyuki Soeda, Misato Yoshikawa, Osborne F X Almeida, Akio Sumioka, Sumihiro Maeda, Hiroyuki Osada, Yasumitsu Kondoh, Akiko Saito, Tomohiro Miyasaka, Tetsuya Kimura, Masaaki Suzuki, Hiroko Koyama, Yuji Yoshiike, Hachiro Sugimoto, Yasuo Ihara, Akihiko Takashim. Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups. Nature communications. vol 6. 2016-05-17. PMID:26671725. |
thus, compounds that target the cysteine residues of tau may prove useful in halting the progression of alzheimer's disease and other tauopathies. |
2016-05-17 |
2023-08-13 |
Not clear |
| Chris Law, Marcos Schaan Profes, Martin Levesque, Julia A Kaltschmidt, Matthijs Verhage, Artur Kani. Normal Molecular Specification and Neurodegenerative Disease-Like Death of Spinal Neurons Lacking the SNARE-Associated Synaptic Protein Munc18-1. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 36. issue 2. 2016-05-17. PMID:26758845. |
finally, we demonstrate pathological similarities to alzheimer's disease, such as altered tau phosphorylation, neurofibrillary tangles, and accumulation of insoluble protein plaques. |
2016-05-17 |
2023-08-13 |
mouse |
| T Yoshimi, S Kawabata, S Taira, A Okuno, R Mikawa, S Murayama, K Tanaka, O Takikaw. Affinity imaging mass spectrometry (AIMS): high-throughput screening for specific small molecule interactions with frozen tissue sections. The Analyst. vol 140. issue 21. 2016-05-12. PMID:26365298. |
as an example application, we screened over a thousand compounds against alzheimer's disease (ad) brain tissue and identified several compounds with high affinity for ad brain sections containing tau deposits compared to age-matched controls. |
2016-05-12 |
2023-08-13 |
human |
| Santosh Chauhan, Zahra Ahmed, Steven B Bradfute, John Arko-Mensah, Michael A Mandell, Seong Won Choi, Tomonori Kimura, Fabien Blanchet, Anna Waller, Michal H Mudd, Shanya Jiang, Larry Sklar, Graham S Timmins, Nicole Maphis, Kiran Bhaskar, Vincent Piguet, Vojo Dereti. Pharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential. Nature communications. vol 6. 2016-05-11. PMID:26503418. |
we identify a subset of pharmaceuticals inducing autophagic flux with effects in diverse cellular systems modelling specific stages of several human diseases such as hiv transmission and hyperphosphorylated tau accumulation in alzheimer's disease. |
2016-05-11 |
2023-08-13 |
human |
| Tina Bilousova, Carol A Miller, Wayne W Poon, Harry V Vinters, Maria Corrada, Claudia Kawas, Eric Y Hayden, David B Teplow, Charles Glabe, Ricardo Albay, Gregory M Cole, Edmond Teng, Karen H Gyly. Synaptic Amyloid-β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases. The American journal of pathology. vol 186. issue 1. 2016-05-10. PMID:26718979. |
amyloid-β (aβ) and hyperphosphorylated tau (p-tau) aggregates form the two discrete pathologies of alzheimer disease (ad), and oligomeric assemblies of each protein are localized to synapses. |
2016-05-10 |
2023-08-13 |
human |
| Yann Fichou, Matthias Heyden, Giuseppe Zaccai, Martin Weik, Douglas J Tobia. Molecular Dynamics Simulations of a Powder Model of the Intrinsically Disordered Protein Tau. The journal of physical chemistry. B. vol 119. issue 39. 2016-05-09. PMID:26351734. |
the tau protein, whose aggregates are involved in alzheimer's disease, is an intrinsically disordered protein (idp) that regulates microtubule activity in neurons. |
2016-05-09 |
2023-08-13 |
Not clear |
| Montasir Elahi, Yumiko Motoi, Shin-Ei Matsumoto, Zafrul Hasan, Koichi Ishiguro, Nobutaka Hattor. Short-term treadmill exercise increased tau insolubility and neuroinflammation in tauopathy model mice. Neuroscience letters. vol 610. 2016-05-09. PMID:26592481. |
physical exercise has been identified as a preventive measure for alzheimer's disease (ad), one of the neuropathological hallmarks of which, neurofibrillary tangles, consist of hyperphosphorylated insoluble tau. |
2016-05-09 |
2023-08-13 |
mouse |
| Qingqin S Li, Antonio R Parrado, Mahesh N Samtani, Vaibhav A Naraya. Variations in the FRA10AC1 Fragile Site and 15q21 Are Associated with Cerebrospinal Fluid Aβ1-42 Level. PloS one. vol 10. issue 8. 2016-05-08. PMID:26252872. |
proteolytic fragments of amyloid and post-translational modification of tau species in cerebrospinal fluid (csf) as well as cerebral amyloid deposition are important biomarkers for alzheimer's disease. |
2016-05-08 |
2023-08-13 |
Not clear |
| Nicha Puangmalai, Alyma Somani, Wipawan Thangnipon, Clive Ballard, Martin Broadstoc. A genetically immortalized human stem cell line: a promising new tool for Alzheimer's disease therapy. EXCLI journal. vol 14. 2016-05-06. PMID:27152108. |
amyloid-β peptides and hyper-phosphorylated tau are the main pathological hallmarks of alzheimer's disease (ad). |
2016-05-06 |
2023-08-13 |
human |
| Keshav Anand, Marwan Sabbag. Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease. Expert opinion on investigational drugs. vol 24. issue 10. 2016-05-05. PMID:26289787. |
early investigational drugs targeting tau protein for the treatment of alzheimer's disease. |
2016-05-05 |
2023-08-13 |
Not clear |
| Mackenzie D Martin, Laurent Calcul, Courtney Smith, Umesh K Jinwal, Sarah N Fontaine, April Darling, Kent Seeley, Lukasz Wojtas, Malathi Narayan, Jason E Gestwicki, Garry R Smith, Allen B Reitz, Bill J Baker, Chad A Dicke. Synthesis, stereochemical analysis, and derivatization of myricanol provide new probes that promote autophagic tau clearance. ACS chemical biology. vol 10. issue 4. 2016-05-03. PMID:25588114. |
the significance is that tau accumulates in a number of neurodegenerative diseases, the most common being alzheimer's disease (ad). |
2016-05-03 |
2023-08-13 |
mouse |
| b' Hala Nehm\\xc3\\xa9, Sandrine Chantepie, Justine Defert, Philippe Morin, Dulce Papy-Garcia, Reine Nehm\\xc3\\xa. New methods based on capillary electrophoresis for in vitro evaluation of protein tau phosphorylation by glycogen synthase kinase 3-\\xce\\xb2. Analytical and bioanalytical chemistry. vol 407. issue 10. 2016-05-03. PMID:25711986.' |
the hyperphosphorylation of tau protein is associated with the development of the neuronal pathology of alzheimer's disease. |
2016-05-03 |
2023-08-13 |
Not clear |
| Sally Hunter, Thais Minett, Tuomo Polvikoski, Elizabeta Mukaetova-Ladinska, Carol Brayn. Re-examining tau-immunoreactive pathology in the population: granulovacuolar degeneration and neurofibrillary tangles. Alzheimer's research & therapy. vol 7. issue 1. 2016-05-03. PMID:26315613. |
alzheimer's disease (ad) is associated with neurofibrillary pathology, including neurofibrillary tangles (nft), neuritic plaques (np) and neuropil threads containing aggregated microtubule associated protein tau. |
2016-05-03 |
2023-08-13 |
Not clear |
| Simon Sjödin, Kerstin K A Andersson, Marc Mercken, Henrik Zetterberg, Herman Borghys, Kaj Blennow, Erik Porteliu. APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment. Alzheimer's research & therapy. vol 7. issue 1. 2016-05-03. PMID:26689589. |
alzheimer's disease brains are characterized by extracellular plaques containing the aggregated amyloid β42 (aβ42) peptide and intraneuronal tangles containing hyperphosphorylated tau. |
2016-05-03 |
2023-08-13 |
Not clear |
| Patricia Aguilar-Calvo, Consolación García, Juan Carlos Espinosa, Olivier Andreoletti, Juan María Torre. Prion and prion-like diseases in animals. Virus research. vol 207. 2016-05-02. PMID:25444937. |
other proteins such as β-amyloid, tau or serum amyloid-a (saa) seem to share with prions some aspects of their pathogenic mechanism; causing a variety of so called prion-like diseases in humans and/or animals such as alzheimer's, parkinson's, huntington's, type ii diabetes mellitus or amyloidosis. |
2016-05-02 |
2023-08-13 |
Not clear |
| Rita Marreiros, Andreas Müller-Schiffmann, Verian Bader, Suganya Selvarajah, Debendranath Dey, Vishwanath R Lingappa, Carsten Kort. Viral capsid assembly as a model for protein aggregation diseases: Active processes catalyzed by cellular assembly machines comprising novel drug targets. Virus research. vol 207. 2016-05-02. PMID:25451064. |
examples for substrates are amyloid β peptide (aβ) and tau in alzheimer's disease, α-synuclein in parkinson's disease, prions in the prion diseases, disrupted-in-schizophrenia 1 (disc1) in subsets of chronic mental illnesses, and others. |
2016-05-02 |
2023-08-13 |
Not clear |
| Ahmed Abdall. Tau protein as a target for Alzheimer's disease management. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society. vol 23. issue 4. 2016-05-02. PMID:27134542. |
tau protein as a target for alzheimer's disease management. |
2016-05-02 |
2023-08-13 |
Not clear |